Bio-Rad acquires AbD Serotec

Tuesday, 15 January, 2013

Bio-Rad Laboratories, a multinational manufacturer and distributor of life science research and clinical diagnostic products, has announced that it has purchased AbD Serotec, a division of MorphoSys, for approximately €53 million in cash.

AbD Serotec is one of the world’s leading antibody manufacturers, offering over 15,000 antibodies, kits and accessories. AbD Serotec has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as other facilities in Germany and the US.

“We are pleased to have AbD Serotec join Bio-Rad,” said Norman Schwartz, Bio-Rad President and CEO.

“With AbD Serotec’s comprehensive catalogue of antibodies, we are able to offer our customers total assay solutions that can be validated on many of our research platforms for western blotting, multiplex protein expression, ELISA and cell sorting.”

Related News

Australian Healthcare Week 2024: register for your free pass

With more than 150 leading health sector speakers, over 100 sessions and two deep-dive master...

Recommendations released: Pathway to Diversity in STEM Review

The Pathway to Diversity in STEM Review addresses the urgent need for Australia to boost its STEM...

Built for the future: KAESER Australia unveils new facility in Vic

The 4500 m2, $15 million facility features various innovations that echo KAESER's...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd